Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ST13
is a cofactor of heat shock protein 70 (Hsp70). To date, all data since the discovery of
ST13
in 1993 until more recent studies in 2007 have proved that
ST13
is downregulated in tumors and it was proposed to be a tumor suppressor gene, but no work reported its antitumor effect and apoptotic mechanism. In the work described in this paper,
ST13
was inserted into ZD55, an oncolytic adenovirus with the E1B 55-kDa gene deleted, to form ZD55-
ST13
, which exerts an excellent antitumor effect in vitro and in an animal model of colorectal carcinoma SW620 xenograft. ZD55-
ST13
inhibited tumor cells 100-fold more than Ad-
ST13
and ZD55-EGFP in vitro. However, ZD55-
ST13
showed no damage of normal fibroblast MRC5 cells. In exploring the mechanism of ZD55-
ST13
in tumor cell killing, we found that ZD55-
ST13
-infected SW620 cells formed apoptotic bodies and presented obvious apoptosis phenomena. ZD55-
ST13
induced the upregulation of Hsp70, the downregulation of antiapoptotic gene Bcl-2, and the release of cytochrome c. Cytochrome c triggered apoptosis by activating
caspase-9
and caspase-3, which cleave the enzyme poly(ADP-ribose) polymerase in ZD55-
ST13
-infected SW620 cells. In summary, overexpressed
ST13
as mediated by oncolytic adenovirus could exert potent antitumor activity via the intrinsic apoptotic pathway and has the potential to become a novel therapeutic for colorectal cancer gene therapy.
...
PMID:Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death. 1835 16